Aclarion, Inc.

ACON · NASDAQ

Aclarion has a distinctive MRS-based spine diagnostic workflow, a stronger post-financing cash balance, and visible CLARITY and payer proof gates, but FY2025 revenue was only $75,730 and the company still has to convert Nociscan from clinical promise into reimbursed repeat volume.

Follow Add to Watchlist Ask Question

NASDAQ ACON Coverage Bootstrap Healthcare Technology Diagnostics Medical Software

Latest ReportMay 13, 2026Aclarion: the $19M cash pile chasing a tiny Nociscan revenue lineView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.